On Monday, Verve Therapeutics Inc (NASDAQ: VERV) was 26.38% up from the session before settling in for the closing price of $3.26. A 52-week range for VERV has been $2.86 – $9.31.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 136.15% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at -13.06%. With a float of $66.12 million, this company’s outstanding shares have now reached $88.76 million.
In an organization with 274 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 84.37%, operating margin of -707.23%, and the pretax margin is -613.51%.
Verve Therapeutics Inc (VERV) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Verve Therapeutics Inc stocks. The insider ownership of Verve Therapeutics Inc is 25.54%, while institutional ownership is 69.95%. The most recent insider transaction that took place on Apr 02 ’25, was worth 40,761. In this transaction Chief Executive Officer of this company sold 9,822 shares at a rate of $4.15, taking the stock ownership to the 346,686 shares. Before that another transaction happened on Apr 02 ’25, when Company’s Chief Administrative Officer sold 2,777 for $4.15, making the entire transaction worth $11,525. This insider now owns 17,420 shares in total.
Verve Therapeutics Inc (VERV) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.67 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -13.06% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.26% during the next five years compared to -42.43% drop over the previous five years of trading.
Verve Therapeutics Inc (NASDAQ: VERV) Trading Performance Indicators
You can see what Verve Therapeutics Inc (VERV) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 12.65. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.32.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.35, a number that is poised to hit -0.64 in the next quarter and is forecasted to reach -2.66 in one year’s time.
Technical Analysis of Verve Therapeutics Inc (VERV)
Let’s dig in a bit further. During the last 5-days, its volume was 8.55 million. That was better than the volume of 2.03 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 37.70%. Additionally, its Average True Range was 0.54.
During the past 100 days, Verve Therapeutics Inc’s (VERV) raw stochastic average was set at 19.55%, which indicates a significant decrease from 41.79% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 160.14% in the past 14 days, which was higher than the 111.62% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.09, while its 200-day Moving Average is $5.90. However, in the short run, Verve Therapeutics Inc’s stock first resistance to watch stands at $4.43. Second resistance stands at $4.74. The third major resistance level sits at $5.18. If the price goes on to break the first support level at $3.68, it is likely to go to the next support level at $3.24. The third support level lies at $2.93 if the price breaches the second support level.
Verve Therapeutics Inc (NASDAQ: VERV) Key Stats
There are 88,796K outstanding shares of the company, which has a market capitalization of 365.86 million. As of now, sales total 32,330 K while income totals -198,710 K. Its latest quarter income was 13,080 K while its last quarter net income were -50,040 K.
